JP2021106585A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021106585A5 JP2021106585A5 JP2021029693A JP2021029693A JP2021106585A5 JP 2021106585 A5 JP2021106585 A5 JP 2021106585A5 JP 2021029693 A JP2021029693 A JP 2021029693A JP 2021029693 A JP2021029693 A JP 2021029693A JP 2021106585 A5 JP2021106585 A5 JP 2021106585A5
- Authority
- JP
- Japan
- Prior art keywords
- pluripotent stem
- human pluripotent
- stem cells
- composition
- cell culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 4
- 238000004113 cell culture Methods 0.000 claims 3
- 108010059616 Activins Proteins 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 102100026818 Inhibin beta E chain Human genes 0.000 claims 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 2
- 239000000488 activin Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229910052711 selenium Inorganic materials 0.000 claims 2
- 239000011669 selenium Substances 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 claims 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 1
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- WXFIGDLSSYIKKV-RCOVLWMOSA-N L-Metaraminol Chemical compound C[C@H](N)[C@H](O)C1=CC=CC(O)=C1 WXFIGDLSSYIKKV-RCOVLWMOSA-N 0.000 claims 1
- 108010056852 Myostatin Proteins 0.000 claims 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 210000002744 extracellular matrix Anatomy 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- -1 nodal Proteins 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 229940091258 selenium supplement Drugs 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims 1
- 229960002431 trimipramine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17173816 | 2017-05-31 | ||
| EP17173816.4 | 2017-05-31 | ||
| JP2018555485A JP6913694B2 (ja) | 2017-05-31 | 2018-05-18 | 多能性幹細胞のための培養培地 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555485A Division JP6913694B2 (ja) | 2017-05-31 | 2018-05-18 | 多能性幹細胞のための培養培地 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021106585A JP2021106585A (ja) | 2021-07-29 |
| JP2021106585A5 true JP2021106585A5 (https=) | 2021-09-16 |
Family
ID=59030771
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555485A Active JP6913694B2 (ja) | 2017-05-31 | 2018-05-18 | 多能性幹細胞のための培養培地 |
| JP2021029693A Withdrawn JP2021106585A (ja) | 2017-05-31 | 2021-02-26 | 多能性幹細胞のための培養培地 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555485A Active JP6913694B2 (ja) | 2017-05-31 | 2018-05-18 | 多能性幹細胞のための培養培地 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12234484B2 (https=) |
| EP (1) | EP3436568B1 (https=) |
| JP (2) | JP6913694B2 (https=) |
| CN (1) | CN109689859A (https=) |
| DK (1) | DK3436568T3 (https=) |
| ES (1) | ES2955861T3 (https=) |
| PL (1) | PL3436568T3 (https=) |
| WO (1) | WO2018219684A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3858980A4 (en) * | 2018-09-28 | 2021-12-08 | Ajinomoto Co., Inc. | CULTURE ADDITIVE, CULTURE MEDIA AND CULTURE PROCESS FOR ANIMAL CELLS |
| EP4130238A4 (en) * | 2020-03-25 | 2024-05-15 | Ajinomoto Co., Inc. | HEPES-CONTAINING MEDIUM |
| CN113388574A (zh) * | 2021-05-12 | 2021-09-14 | 生物岛实验室 | 一种有效抑制干细胞分化的无血清、无饲养层培养基及培养方法 |
| WO2024059776A2 (en) * | 2022-09-16 | 2024-03-21 | Vertex Pharmaceuticals Incorporated | Enhanced differentiation of pancreatic islet cells |
| CN118374442B (zh) * | 2024-05-14 | 2025-07-15 | 北京同立海源生物科技有限公司 | 一种成分确定的间充质干细胞无血清培养基及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG170021A1 (en) | 2006-02-23 | 2011-04-29 | Novocell Inc | Compositions and methods useful for culturing differentiable cells |
| GB0613756D0 (en) * | 2006-07-12 | 2006-08-23 | Univ Sheffield | Cell culture medium |
| GB0701970D0 (en) * | 2007-02-01 | 2007-03-14 | Wilson Stuart | Treatment of protein aggregation diseases |
| JP6148429B2 (ja) * | 2011-01-31 | 2017-06-14 | 協和発酵バイオ株式会社 | ヒト多能性幹細胞の培養方法 |
| GB201117469D0 (en) * | 2011-10-10 | 2011-11-23 | Cell Guidance Systems Ltd | Culture media for pluripotent stem cells |
| CA2866590A1 (en) * | 2012-03-07 | 2013-09-12 | Janssen Biotech, Inc. | Defined media for expansion and maintenance of pluripotent stem cells |
| SG11201505965TA (en) * | 2013-01-31 | 2015-09-29 | Ajinomoto Kk | Culture method for stable undifferentiated proliferation of pluripotent stem cells |
| KR20160125352A (ko) * | 2013-12-20 | 2016-10-31 | 이센셜 파마수티컬스 엘엘씨 | 세포 배양용 배지 |
-
2018
- 2018-05-18 JP JP2018555485A patent/JP6913694B2/ja active Active
- 2018-05-18 CN CN201880003455.5A patent/CN109689859A/zh active Pending
- 2018-05-18 PL PL18729341.0T patent/PL3436568T3/pl unknown
- 2018-05-18 US US16/096,806 patent/US12234484B2/en active Active
- 2018-05-18 WO PCT/EP2018/063036 patent/WO2018219684A1/en not_active Ceased
- 2018-05-18 ES ES18729341T patent/ES2955861T3/es active Active
- 2018-05-18 EP EP18729341.0A patent/EP3436568B1/en active Active
- 2018-05-18 DK DK18729341.0T patent/DK3436568T3/da active
-
2021
- 2021-02-26 JP JP2021029693A patent/JP2021106585A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021106585A5 (https=) | ||
| Dan et al. | The influence of cellular source on periodontal regeneration using calcium phosphate coated polycaprolactone scaffold supported cell sheets | |
| Thorp et al. | Fabrication of hyaline-like cartilage constructs using mesenchymal stem cell sheets | |
| Lei et al. | Mesenchymal stem cell characteristics of dental pulp and periodontal ligament stem cells after in vivo transplantation | |
| Baragi et al. | Transplantation of adenovirally transduced allogeneic chondrocytes into articular cartilage defects in vivo | |
| Wu et al. | Age-related decline in the matrix contents and functional properties of human periodontal ligament stem cell sheets | |
| Iwasaki et al. | Periodontal regeneration using periodontal ligament stem cell-transferred amnion | |
| Keogh et al. | Substrate stiffness and contractile behaviour modulate the functional maturation of osteoblasts on a collagen–GAG scaffold | |
| Liu et al. | Dental follicle cells rescue the regenerative capacity of periodontal ligament stem cells in an inflammatory microenvironment | |
| Nakamura | Recent progress in organoid culture to model intestinal epithelial barrier functions | |
| Guo et al. | A novel porcine acellular dermal matrix scaffold used in periodontal regeneration | |
| Iwasaki et al. | Changes in characteristics of periodontal ligament stem cells in spheroid culture | |
| Guo et al. | Limbal niche cells are a potent resource of adult mesenchymal progenitors | |
| Okamura et al. | Promoting effect of basic fibroblast growth factor in synovial mesenchymal stem cell-based cartilage regeneration | |
| Arroyo et al. | Carboxy-terminal cementum protein 1-derived peptide 4 (cemp1-p4) promotes mineralization through wnt/β-catenin signaling in human oral mucosa stem cells | |
| Jung et al. | Optimal medium formulation for the long‐term expansion and maintenance of human periodontal ligament stem cells | |
| Voisin et al. | Are the immune properties of mesenchymal stem cells from Wharton’s jelly maintained during chondrogenic differentiation? | |
| Saini et al. | Coconut milk and probiotic milk as storage media to maintain periodontal ligament cell viability: an in vitro study | |
| Rose et al. | Salivary gland bioengineering | |
| Song et al. | A study of enamel matrix proteins on differentiation of porcine bone marrow stromal cells into cementoblasts | |
| Wang et al. | Restoring osteochondral defects through the differentiation potential of cartilage stem/progenitor cells cultivated on porous scaffolds | |
| Vu et al. | Investigating the effects of conditioned media from stem cells of human exfoliated deciduous teeth on dental pulp stem cells | |
| Dziedzic et al. | Adipose-derived stromal cells and mineralized extracellular matrix delivery by a human decellularized amniotic membrane in periodontal tissue engineering | |
| Nameroff et al. | Contact-mediated reversible suppression of myogenesis | |
| Kushioka et al. | A novel and efficient method for culturing mouse nucleus pulposus cells |